Vaccines Enabling HIV Prevention Targeting Germinal Center Enhancement with Engineered Slow Release Nanoparticles
Award Notice Posted
- Solicitation number
- PHS-2020-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Nanocomposix, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020C00013 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
NANOCOMPOSIX, INC. was awarded a $300,000 contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases to develop vaccines utilizing engineered slow release nanoparticles targeting the germinal center to enhance HIV prevention over a one year period. The contract supports research into vaccines employing nanoparticles designed to gradually release compounds aimed at boosting the body's germinal center immune response against HIV/AIDS, under contract number 75N93020C00013.
Notice text
Awarded contract 75N93020C00013 to NANOCOMPOSIX, INC. for 300000.00 on 2020-06-01.
Notice history
5 of 7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity